NASDAQ:SVRA - Savara Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.68 -0.01 (-0.08 %)
(As of 07/20/2018 02:49 PM ET)
Previous Close$12.69
Today's Range$12.64 - $13.14
52-Week Range$5.07 - $17.19
Volume5,182 shs
Average Volume344,345 shs
Market Capitalization$379.91 million
P/E Ratio-7.21
Dividend YieldN/A
Savara logoSavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.16
Current Ratio16.28
Quick Ratio16.28


Trailing P/E Ratio-7.21
Forward P/E Ratio-9.46
P/E GrowthN/A

Sales & Book Value

Annual Sales$130,000.00
Price / Sales3,008.09
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book3.24


EPS (Most Recent Fiscal Year)($1.76)
Net Income$-29,790,000.00
Net MarginsN/A
Return on Equity-38.69%
Return on Assets-26.66%


Outstanding Shares30,840,000
Market Cap$379.91

Savara (NASDAQ:SVRA) Frequently Asked Questions

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) announced its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.01. View Savara's Earnings History.

What price target have analysts set for SVRA?

7 analysts have issued twelve-month price objectives for Savara's shares. Their forecasts range from $20.00 to $40.00. On average, they expect Savara's share price to reach $27.7143 in the next twelve months. This suggests a possible upside of 118.6% from the stock's current price. View Analyst Ratings for Savara.

What is the consensus analysts' recommendation for Savara?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Savara stock?

Here are some recent quotes from research analysts about Savara stock:
  • 1. According to Zacks Investment Research, "Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. " (6/23/2018)
  • 2. Canaccord Genuity analysts commented, "We see Savara setting up for several important data catalysts that could start flowing through by the end of 2018 and throughout 2019. Savara’s three core programs – Molgradex PAP, Molgradex NTM and AeroVanc – give it several shots on goal for rare pulmonary diseases and make for an increasingly interesting biotech story that’s starting to gain notice in the investment community. We reiterate our BUY rating and $25 DCF- driven PT on SVRA shares." (5/10/2018)

Are investors shorting Savara?

Savara saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 2,099,430 shares, an increase of 182.4% from the June 15th total of 743,347 shares. Based on an average daily volume of 638,070 shares, the days-to-cover ratio is currently 3.3 days. Approximately 9.0% of the shares of the company are sold short. View Savara's Current Options Chain.

Who are some of Savara's key competitors?

Who are Savara's key executives?

Savara's management team includes the folowing people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

Has Savara been receiving favorable news coverage?

News headlines about SVRA stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Savara earned a media sentiment score of 0.17 on Accern's scale. They also assigned news stories about the company an impact score of 45.92 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Savara's major shareholders?

Savara's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.10%) and Essex Investment Management Co. LLC (0.09%). Company insiders that own Savara stock include David L Lowrance, Jaakko Taneli Jouhikainen, Joseph S Mccracken, Robert N Neville and Yuri Pikover. View Institutional Ownership Trends for Savara.

Which institutional investors are buying Savara stock?

SVRA stock was purchased by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc. and Essex Investment Management Co. LLC. Company insiders that have bought Savara stock in the last two years include David L Lowrance, Jaakko Taneli Jouhikainen, Joseph S Mccracken and Yuri Pikover. View Insider Buying and Selling for Savara.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $12.68.

How big of a company is Savara?

Savara has a market capitalization of $379.91 million and generates $130,000.00 in revenue each year. The company earns $-29,790,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Savara employs 24 workers across the globe.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected]

MarketBeat Community Rating for Savara (NASDAQ SVRA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.